EntryPoint Capital LLC Invests $186,000 in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• EntryPoint Capital LLC invested approximately $186,000 in Eyepoint Pharmaceuticals, acquiring 34,324 shares of the company's stock in the first quarter.
• Eyepoint Pharmaceuticals reported a loss of $0.85 earnings per share for the last quarter, missing the consensus estimate, with a negative net margin of 337.93%.
• Analyst ratings show a consensus "Buy" rating for Eyepoint Pharmaceuticals, with an average target price of $25.38, despite recent price target adjustments from several firms.

EntryPoint Capital LLC acquired a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 34,324 shares of the company's stock, valued at approximately $186,000.

Other hedge funds have also recently made changes to their positions in the company. Suvretta Capital Management LLC boosted its stake in Eyepoint Pharmaceuticals by 31.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock valued at $50,534,000 after buying an additional 1,607,268 shares during the last quarter. Federated Hermes Inc. boosted its stake in Eyepoint Pharmaceuticals by 10.2% during the first quarter. Federated Hermes Inc. now owns 4,085,580 shares of the company's stock valued at $22,144,000 after buying an additional 378,135 shares during the last quarter. Vanguard Group Inc. boosted its stake in Eyepoint Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock valued at $20,782,000 after buying an additional 31,141 shares during the last quarter. TCG Crossover Management LLC boosted its stake in Eyepoint Pharmaceuticals by 287.3% during the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after buying an additional 2,650,000 shares during the last quarter. Finally, RA Capital Management L.P. bought a new position in Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $23,705,000. Institutional investors own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $11.83 on Monday. The firm has a market capitalization of $815.44 million, a price-to-earnings ratio of -4.41 and a beta of 1.73. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.98. The business has a 50 day simple moving average of $10.16 and a 200-day simple moving average of $7.68.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The company had revenue of $5.33 million during the quarter, compared to the consensus estimate of $6.82 million. As a group, analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Mizuho dropped their price target on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. Chardan Capital reissued a "buy" rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Royal Bank Of Canada assumed coverage on Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target for the company. Finally, HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $25.38.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.